DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) — MannKind Company (Nasdaq: MNKD) will release its third quarter 2022 and year-to-date financial results and its management will host a conference call to discuss these results and business updates at 9:00 a.m. (Eastern Time) on Tuesday, November 8 2022.
Presenting the company will be its CEO, Michael Castagna and Chief Financial Officer, Steven Binder.
Those interested in listening to the conference call live via the Internet may do so by visiting the Company’s website at https://mannkindcorp.com/news-events/ under Events and Presentations.
MannKind Corporation (Nasdaq: MNKD) is focused on developing and commercializing innovative therapeutic products and devices to address the serious unmet medical needs of people with orphan endocrine and lung diseases.
We are committed to using our formulation capabilities and device engineering prowess to reduce the burden of diseases such as diabetes, pulmonary arterial hypertension (PAH), and non-tuberculous mycobacterial lung disease (NCD). Our signature technologies – dry powder formulations and inhalation devices – enable rapid and convenient delivery of drugs to the deep lungs where they can exert an effect locally or enter the systemic circulation.
With a passionate team of Healthcare Providers collaborating nationwide, we’re on a mission to give people control of their health and the freedom to live their lives.
Rose Alinaya, Investor Relations
E-mail: [email protected]